Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 66


A Cost Analysis of Tolerance Induction for Two-Haplotype Match Kidney Transplant Recipients.

Erickson KF, Winkelmayer WC, Busque S, Lowsky R, Scandling JD, Strober S.

Am J Transplant. 2016 Jan;16(1):371-3. doi: 10.1111/ajt.13530. Epub 2015 Nov 9. No abstract available.


Loss of function mutation of the Slc38a3 glutamine transporter reveals its critical role for amino acid metabolism in the liver, brain, and kidney.

Chan K, Busque SM, Sailer M, Stoeger C, Bröer S, Daniel H, Rubio-Aliaga I, Wagner CA.

Pflugers Arch. 2016 Feb;468(2):213-27. doi: 10.1007/s00424-015-1742-0.


Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation.

Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, Jensen K, Shori A, Strober JA, Lavori P, Turnbull BB, Engleman EG, Strober S.

Am J Transplant. 2015 Mar;15(3):695-704. doi: 10.1111/ajt.13091.


Longitudinal study of living kidney donor glomerular dynamics after nephrectomy.

Lenihan CR, Busque S, Derby G, Blouch K, Myers BD, Tan JC.

J Clin Invest. 2015 Mar 2;125(3):1311-8. doi: 10.1172/JCI78885. Epub 2015 Feb 17.


Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients.

Vincenti F, Silva HT, Busque S, O'Connell PJ, Russ G, Budde K, Yoshida A, Tortorici MA, Lamba M, Lawendy N, Wang W, Chan G.

Am J Transplant. 2015 Jun;15(6):1644-53. doi: 10.1111/ajt.13181. Epub 2015 Feb 3.


The association of predonation hypertension with glomerular function and number in older living kidney donors.

Lenihan CR, Busque S, Derby G, Blouch K, Myers BD, Tan JC.

J Am Soc Nephrol. 2015 Jun;26(6):1261-7. doi: 10.1681/ASN.2014030304. Epub 2014 Dec 18.


Dysregulation of the glutamine transporter Slc38a3 (SNAT3) and ammoniagenic enzymes in obese, glucose-intolerant mice.

Busque SM, Stange G, Wagner CA.

Cell Physiol Biochem. 2014;34(2):575-89. doi: 10.1159/000363024. Epub 2014 Aug 11.


A preconditioning regimen with a PKCɛ activator improves islet graft function in a mouse transplant model.

Hamilton D, Rugg C, Davis N, Kvezereli M, Tafti BA, Busque S, Fontaine M.

Cell Transplant. 2014;23(7):913-9. doi: 10.3727/096368913X665567. Epub 2013 Apr 2.


Evaluating deceased donor registries: identifying predictive factors of donor designation.

Hajhosseini B, Stewart B, Tan JC, Busque S, Melcher ML.

Am Surg. 2013 Mar;79(3):235-41.


Desensitization combined with paired exchange leads to successful transplantation in highly sensitized kidney transplant recipients: strategy and report of five cases.

Yabu JM, Pando MJ, Busque S, Melcher ML.

Transplant Proc. 2013 Jan-Feb;45(1):82-7. doi: 10.1016/j.transproceed.2012.08.007.


Chain transplantation: initial experience of a large multicenter program.

Melcher ML, Leeser DB, Gritsch HA, Milner J, Kapur S, Busque S, Roberts JP, Katznelson S, Bry W, Yang H, Lu A, Mulgaonkar S, Danovitch GM, Hil G, Veale JL.

Am J Transplant. 2012 Sep;12(9):2429-36. doi: 10.1111/j.1600-6143.2012.04156.x. Epub 2012 Jul 19.


Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, Kim YS, Lawendy N, Lan SP, Kudlacz E, Krishnaswami S, Chan G.

Am J Transplant. 2012 Sep;12(9):2446-56. doi: 10.1111/j.1600-6143.2012.04127.x. Epub 2012 Jun 8.


Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants.

Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Sarwal M, Millan MT, Shizuru JA, Lowsky R, Engleman EG, Strober S.

Am J Transplant. 2012 May;12(5):1133-45. doi: 10.1111/j.1600-6143.2012.03992.x. Epub 2012 Mar 8.


Incidental kidney stones: a single center experience with kidney donor selection.

Kim IK, Tan JC, Lapasia J, Elihu A, Busque S, Melcher ML.

Clin Transplant. 2012 Jul-Aug;26(4):558-63. doi: 10.1111/j.1399-0012.2011.01567.x. Epub 2011 Dec 14.


Validity of surrogate measures for functional nephron mass.

Tan JC, Paik J, Chertow GM, Grumet FC, Busque S, Lapasia J, Desai M.

Transplantation. 2011 Dec 27;92(12):1335-41. doi: 10.1097/TP.0b013e31823705ef.


Induced immune tolerance for kidney transplantation.

Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S.

N Engl J Med. 2011 Oct 6;365(14):1359-60. doi: 10.1056/NEJMc1107841. No abstract available.


The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation.

Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators.

Am J Transplant. 2011 Dec;11(12):2675-84. doi: 10.1111/j.1600-6143.2011.03763.x. Epub 2011 Sep 22.


Managing finances of shipping living donor kidneys for donor exchanges.

Mast DA, Vaughan W, Busque S, Veale JL, Roberts JP, Straube BM, Flores N, Canari C, Levy E, Tietjen A, Hil G, Melcher ML.

Am J Transplant. 2011 Sep;11(9):1810-4. doi: 10.1111/j.1600-6143.2011.03690.x. Epub 2011 Aug 10.


Debate: PRO Position. Formal assessment of donor kidney function should be mandatory.

Tan JC, Busque S, Ho B, Myers BD.

Am J Nephrol. 2011;33(3):198-200; discussion 205. doi: 10.1159/000323230. Epub 2011 Feb 18. No abstract available.


C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation.

Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB.

Transplantation. 2011 Feb 15;91(3):342-7. doi: 10.1097/TP.0b013e318203fd26.

Items per page

Supplemental Content

Loading ...
Support Center